INHIBITORY EFFECT OF LIDOCAINE ON COLONIC SPASM DURING COLONOSCOPY: A MULTICENTER DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL (WITH A VIDEO)

DOI
  • NEMOTO Daiki
    Department of Coloproctology, Aizu Medical Center, Fukushima Medical University.
  • SUZUKI Sho
    Department of Gastrointestinal Oncology, Osaka International Cancer Institute.
  • MORI Hideki
    Departments of Gastroenterology, National Hospital Organization Tokyo Medical Center.
  • KATSUKI Shinichi
    Otaru Ekisaikai Hospital.
  • IWAKI Tomoyuki
    Department of Endoscopy, Sendai Kousei Hospital.
  • AIZAWA Masato
    Department of Coloproctology, Aizu Medical Center, Fukushima Medical University.
  • TAKEUCHI Yoji
    Department of Gastrointestinal Oncology, Osaka International Cancer Institute.
  • URAOKA Toshio
    Departments of Gastroenterology, National Hospital Organization Tokyo Medical Center.
  • MATSUDA Tomoki
    Department of Endoscopy, Sendai Kousei Hospital.
  • FUJITA Tomoki
    Otaru Ekisaikai Hospital.
  • HEWETT David G.
    Faculty of Medicine, the University of Queensland.
  • TOGASHI Kazutomo
    Department of Coloproctology, Aizu Medical Center, Fukushima Medical University.

Bibliographic Information

Other Title
  • 大腸内視鏡検査におけるリドカインの腸管蠕動抑制効果：多施設，二重盲検，ランダム化比較試験（動画付き）

Search this article

Description

<p>Objectives: Colonic spasm can interfere with colonoscopy, but antispasmodic agents can cause complications. This study aimed to assess the inhibitory effect of topical lidocaine compared with a placebo control.</p><p>Methods: In five tertiary-care hospitals in Japan, 128 patients requiring endoscopic resection of a colorectal lesion were enrolled and randomly and double-blindly allocated to colonoscopy with topical administration of 2% lidocaine solution 20mL (LID, n=64) or normal saline 20mL (control, n=64). During colonoscopy, the assigned solution was applied with a spray catheter near the lesion and the area was observed for three minutes. Primary endpoint was the inhibitory effect at three time-points (1, 2 and 3 minutes after dispersion), using a three-point scale (excellent, fair, poor). Secondary endpoints were rebound spasm and adverse events. All endpoints were scored in real time. Serum lidocaine levels were measured in 32 patients (LID 16, control 16).</p><p>Results: There were no significant differences between groups in patient demographics. At all time-points, the proportion of patients with “excellent” scores was greater in LID group than control group, with significant differences observed at 2 minutes (p=0.02) and 3 minutes (p=0.02). In LID group, the rate of “excellent” scores increased by 12.5% at 2 minutes and was maintained at 3 minutes. Rebound spasm did not occur in LID group, compared with 15.6% of control group (p=0.001). There were no adverse events in LID group. All serum lidocaine levels were below detectable levels.</p><p>Conclusions: Topical lidocaine is an effective and safe method for suppressing colorectal spasm during colonoscopy (UMIN000024733).</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top